In a previous retrospective analysis for quality assessment in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, we demonstrated the robust performance characteristics of an NGS assay using the AmpliSeq Cancer Hotspot Panel and Personal Genome Machine to detect a panel of KRAS, NRAS, BRAF, and PIK3CA genes (CRC panel) for prediction of anti-EGFR resistance [30, 31]. The gene discussed is PIK3CA; the disease is colorectal carcinoma.